Wells Fargo analyst Colin Langan maintains Cerence (NASDAQ:CRNC) with a Overweight and raises the price target from $25 to $32.
Cantor Fitzgerald Maintains Neutral on MedMen Enterprises, Lowers Price Target to $0.25
Cantor Fitzgerald analyst Pablo Zuanic maintains MedMen Enterprises (OTC:MMNFF) with a Neutral and lowers the price target from $0.3 to $0.25.